Cargando…

Clinical development of anti-RANKL therapy

The receptor activator of nuclear factor-κB ligand (RANKL), its cognate receptor RANK, and its natural decoy receptor osteoprotegerin have been identified as the final effector molecules of osteoclastic bone resorption. This has provided an ideal target for therapeutic interventions in metabolic bon...

Descripción completa

Detalles Bibliográficos
Autores principales: Schwarz, Edward M, Ritchlin, Christopher T
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2007
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1924522/
https://www.ncbi.nlm.nih.gov/pubmed/17634146
http://dx.doi.org/10.1186/ar2171